Valvular heart disease (VHD), caused by abnormalities in heart valves, can lead to severe complications such as heart failure and death, with approximately 220 million affected patients worldwide. The prevalence of VHD continues to grow alongside the aging global population. Transcatheter heart valve interventions have emerged as minimally invasive alternatives, offering benefits like shorter recovery times and reduced discomfort. However, current manual catheter-based techniques are complex, highly dependent on clinicians' expertise, and involve significant physical risk due to prolonged exposure to X-ray radiation and cumbersome protective gear. To address these challenges, a novel, universal intracardiac robotic system is proposed to improve precision, safety, and procedural efficiency. This system integrates a high-dexterity, load-capacity catheter instrument, a modular concentric robotic platform, and an augmented reality (AR) navigation interface. The catheter's design balances flexibility for navigating complex intracardiac paths with the rigidity needed for device deployment. The robotic platform's modular architecture enhances versatility, enabling control across various procedures and anatomical variations, while the AR system facilitates intuitive preoperative planning and real-time intraoperative guidance through multimodal image fusion. The core innovation lies in overcoming existing limitations: balancing catheter flexibility and load capacity, expanding robotic system adaptability for different valve procedures, and improving integration with imaging modalities like computed tomography, transesophageal echocardiogram, and fluoroscopy. The project aims to develop sophisticated models for instrument design, control strategies for multi-instrument coordination, and advanced navigation tools. These technological advancements are intended to elevate the clinical utility of robotic intracardiac interventions, making them safer, more efficient, and easier to adopt widely. By establishing a systematic approach for intelligent, multimodal, robotic-assisted valvular procedures, this work promises significant contributions to minimally invasive cardiology and holds substantial potential for clinical translation.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Rate of Intraprocedural success according to TVARC
Timeframe: Intra-operation
Rate of major adverse events: cardiovascular mortality
Timeframe: 30 day post-operation
Rate of major adverse events: myocardial infarction
Timeframe: 30 day post-operation
Rate of major adverse events: stroke
Timeframe: 30 day post-operation
Rate of major adverse events: renal complication
Timeframe: 30 day post-operation
Rate of major adverse events: severe bleeding
Timeframe: 30 day post-operation
Rate of major adverse events: nonelective Tricuspid Valve reintervention
Timeframe: 30 day post-operation
Rate of major adverse events: major vascular complications
Timeframe: 30 day post-operation
Rate of major adverse events: major cardiac structural complications
Timeframe: 30 day post-operation
Rate of major adverse events: device-related pulmonary embolism
Timeframe: 30 day post-operation